DALLAS, TEXAS- Diana Anderson, Ph.D., president and CEO of patient recruitment and retention firm D. Anderson & Company (DAC), has been named to the first editorial board of R&D Directions. Published since 1995, R&D Directions provides extensive coverage of pharmaceutical research and development, from discovery and clinical trials to drug application and market debut. The newly created editorial board is composed of 11 industry experts who represent a cross-section of the magazine’s readership and provide guidance on the publication’s tone and content.
Dr. Anderson will serve on the editorial board alongside executives from Xceleron, Deloitte Consulting, AstraZeneca, Amgen, Healthcare Communications Group, Merck & Co., Acurian Inc., Southern Research Institute, Charles River Laboratories as well as a former VP from Roche.
During her tenure at the helm of DAC, Dr. Anderson has positioned the company as an international player in clinical trials, boasting expertise in several therapeutic areas. The company began more than 18 years ago as a site management organization and evolved into one of the largest privately held patient recruitment and retention firms in the United States.
Dr. Anderson’s achievements have been profiled by Thomson CenterWatch, as well as other business media. In 2006,
PharmaVOICE named her one of the “100 Most Inspiring People” in the life sciences industry. She was also nominated for the Ernst & Young Entrepreneur of the Year in 2007.
An accomplished author, Dr. Anderson has penned four industry must-reads, including “A Guide to Patient Recruitment” and “A Guide to Patient Recruitment and Retention.” The depth and breadth of her expertise is captured in her latest text, “International Patient Recruitment Regulatory Guidelines, Customs and Practices,” which provides an expository view of legislation governing patient recruitment in 23 countries.
D. Anderson & Company (DAC) is a leading provider of global patient recruitment and retention services for the clinical trials industry with more than 18 years of experience in more than 40 countries. DAC is a subsidiary of D.L. Anderson International, Inc. The company evolved from a clinical background as a site management organization (SMO), giving it a unique understanding of how sites operate and what they need to reach enrollment goals within targeted timelines. DAC combines strategic marketing, messaging and branding solutions with proven, data-driven methodologies to create targeted patient recruitment campaigns for some of the most prestigious pharmaceutical and biotechnology companies in the world. The company is certified as a Women-Owned Business (WBE) by the Women’s Business Enterprise National Council. DAC has offices in Seattle, Houston and Dallas. For more information, visit www.dandersoncompany.com
